Document:

<PAGE>   1

              Certain Confidential Information has been omitted
                  and filed separately with the Commission.

SALSBURY CHEMICALS
------------------
A CAMBREX COMPANY

                                                                   EXHIBIT 10.32

                                SUPPLY AGREEMENT

     THIS AGREEMENT (the "Agreement"), entered into as of this ninth day of
November, 1999 (the "Effective Date"), by and among SALSBURY CHEMICALS, INC.
("Salsbury"), a corporation organized under the laws of Iowa with a place of
business at 1205 11th Street, Charles City, Iowa 50616-3466 and GELTEX
PHARMACEUTICALS, INC., a Delaware corporation with a place of business at 153
Second Avenue, Waltham, MA 02451 ("GelTex" or "Purchaser").

                              W I T N E S S E T H:
                              --------------------

     WHEREAS, GelTex has sublicensed certain patent rights (the "Patent Rights")
obtained from Nitto Boseki Co. Ltd. ("Nittobo") to Salsbury pursuant to the
terms of a sublicense agreement dated July 10, 1997 (the "Sublicense Agreement")
and Salsbury has experience in the production of poly(allylamine hydrochloride),
as further described in Exhibit A hereto (the "Product");

     WHEREAS, Salsbury is a wholly owned subsidiary of Cambrex Corporation, a
corporation organized under the laws of Delaware ("Cambrex"), and Cambrex is the
parent corporation of Nordic Synthesis (Sweden) and certain other companies.

     WHEREAS, for purposes of this Agreement, the term "Affiliate" shall mean
any corporation or other entity that controls, is controlled by, or is under
common control with a party. A corporation or other entity shall be regarded as
in control of another corporation or entity if it owns or directly or indirectly
controls more than fifty percent (50%) of the voting stock or other ownership
interest of the other corporation or entity, or if it possesses directly or
indirectly, the power to direct or cause the direction of the management and
policies of the corporation or other entity or the power to elect or appoint
more than fifty percent (50%) of the members of the governing body of the
corporation or other entity.

     WHEREAS, GelTex requires the Product for the production of RenaGel(R)
non-absorbed phosphate binder and CholestaGel(R) non-absorbed cholesterol
reducer (RenaGel(R) and CholestaGel(R) may hereinafter be referred to
collectively as "End Products");

     WHEREAS, the End Products will be manufactured by certain third party
manufacturers identified in writing to Salsbury (the "Contract Manufacturers")
and will be marketed and sold by certain third party collaborators identified in
writing to Salsbury (the "Collaborators");

     WHEREAS, Salsbury is willing to sell to GelTex and GelTex is willing to
purchase from Salsbury, Product manufactured by Salsbury in accordance with the
price and other terms set forth herein.

     NOW, THEREFORE, the parties hereto agree as follows:

<PAGE>   2
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 2 of 15

ARTICLE I
MANUFACTURE AND SALE
--------------------

     1.01 SUPPLY. During the term of this Agreement and subject to the terms and
          conditions set forth herein, Salsbury shall manufacture and supply to
          GelTex and GelTex shall purchase [                        ]* of its
          annual requirements of the Product from Salsbury. For purposes hereof,
          GelTex's annual requirements shall include the annual requirements of
          the Collaborators and Contract Manufacturers to which GelTex is
          obligated to supply the Product.

     1.02 QUALITY OF PRODUCT. Salsbury agrees to manufacture the Product to meet
          the specifications set forth in Exhibit A hereto (the
          "Specifications"), and in accordance with all applicable regulatory
          requirements relating to the manufacture of the Product and the terms
          and conditions of a Technical Agreement to be entered into between the
          parties in a form substantially similar to that attached hereto as
          Exhibit B (the "Technical Agreement"), and shall not deviate in any
          way whatsoever therefrom without the written permission of a duly
          authorized representative of the Purchasers.

     1.03 SECONDARY SOURCE OF SUPPLY. Following Nittobo's approval to sublicense
          the Patent Rights to a Cambrex Affiliate, Salsbury will make best
          efforts to qualify Nordic Synthesis (Sweden) and / or another Cambrex
          Affiliate as a secondary supplier of Product. Following such
          qualification, Salsbury shall use such secondary supplier of Product
          to manufacture such portion [                   ]* as Salsbury shall
          determine. Notwithstanding its use of a secondary source of supply,
          Salsbury shall remain obligated to supply GelTex with the quantities
          of Product described in Section 1.01, and Salsbury shall be
          responsible for ensuring that all Product manufactured for GelTex,
          whether by Salsbury or another Affiliate of Cambrex, satisfies the
          quality requirements and meets the warranties sets forth in this
          Agreement. If requested by GelTex, Salsbury shall use best efforts to
          cause the secondary source to enter into a Technical Agreement with
          GelTex.

ARTICLE II
TERM
----

     2.01 TERM. The term of this Agreement shall commence on the Effective Date
          and shall terminate [           ]* from the Effective Date hereof
          (the "Initial Term"), and is not subject to earlier cancellation by
          either party except as otherwise specifically provided herein.

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB

* Confidential information omitted and filed separately with the Commission

<PAGE>   3
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 3 of 15

     2.02 RENEWAL TERM. The Agreement shall automatically renew after the
          Initial Term and continue in effect for one-year periods (each such
          period being a "Renewal Term").

     2.03 CANCELLATION. Should GelTex desire to cancel the Agreement at the end
          of the Initial Term or at the end of any Renewal Term, then GelTex
          must provide written notice of cancellation [        ]* prior to
          the termination date of the Initial Term or the relevant Renewal Term,
          as the case may be. Should Salsbury desire to cancel the Agreement at
          the end of the Initial Term or at the end of any Renewal Term then
          Salsbury must provide written notice of cancellation [        ]*
          months prior to the termination date of the Initial Term or the
          relevant Renewal Term, as the case may be. Should Salsbury terminate
          this Agreement, Salsbury agrees to use reasonable efforts to secure
          for GelTex an alternate supplier of the Product.

     2.04 EXTENSION. Salsbury or GelTex has the option to open negotiations on
          the extension of this Agreement two (2) years prior to its expiration.

ARTICLE III
PRICE, ORDERS AND TERMS OF PAYMENT
----------------------------------

     3.01 PRICE. The price (Base Price) for the Product is [               ]*
          per kilogram for calendar year 2000 and a price not to exceed
          [        ]* per kilogram for the remainder of the Initial Term and
          any Renewal Term [                                               ]*.

     3.02 MINIMUM ANNUAL PURCHASE. Commencing in calendar year 2000, Salsbury
          agrees to manufacture and GelTex shall purchase a minimum of
          [                        ]* kilograms of Product during each calendar
          year of the Initial Term and during any Renewal Term. [  ]* kilograms,
          GelTex will make a cash payment to Salsbury such that the total
          revenue for Salsbury from the sale of Product and the cash payment
          will be at least [               ]*.

     3.03 PRICE REVISION. The Base Price will be subject to an annual
          adjustment, commencing on January 1, 2001. That portion of the Base
          Price representing [                  ]*  will be adjusted upward or
          downward based upon [                    ]* for the upcoming year. At
          the end of each contract year, [

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential information omitted and filed separately with the Commission

<PAGE>   4
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 4 of 15

                         ]* be determined and any difference will be invoiced
          to GelTex or credit made to its account. The price for [          ]*
          for calendar year 2001 is [                                     ]*
          (plus freight, insurance and applicable duty). GelTex has the
          option to independently negotiate the price and supply of
          [          ]* and have the price differential incorporated in any new
          Product sales price calculations. The balance of the Base Price will
          be further adjusted upward or downward each year [
                                                                           ]*.

     3.04 PROJECTIONS. GelTex shall issue at quarterly intervals a twelve (12)
          month forecast estimating its total requirements of Product from
          Salsbury. Salsbury will use these forecasts for planning purposes
          only, unless and until such time as GelTex issues a firm purchase
          order for delivery of Product. If during any quarter, the quantity set
          forth in firm purchase orders requested by GelTex exceeds the most
          recent forecast provided for such quarter by more than [
                 ]* Salsbury shall use its best efforts to accommodate any
          increases in the quantity of Product which GelTex shall request under
          new purchase orders.

     3.05 PURCHASE ORDERS. GelTex shall submit purchase orders for quantities of
          Product desired to Salsbury at its address designated in Section 9.06
          hereof. Such purchase orders shall set forth the quantities of Product
          to be purchased, the delivery dates and shipping instructions and
          place of delivery, and shall allow at least [          ]* days for
          delivery. Each purchase order issued hereunder shall be governed by
          the terms of this Agreement, and none of the terms or conditions of
          GelTex's or Salsbury's forms shall be applicable, except for those
          specifying quantity ordered, delivery dates, special supply and
          packing instructions, and invoice instruction.

     3.06 PAYMENT TERMS. Except as set forth at Section 4.03 herein, net payment
          for the Product shall be due to Salsbury not later than thirty (30)
          days from the date of invoice of Product by Salsbury. All payments and
          communications regarding the Product shall be delivered to Salsbury at
          the address designated in Section 9.06 hereof.

     3.07 COMPETITION CLAUSE. On or after January 1, 2002 and after demand for
          Product exceeds [                                  ]* kilograms per
          calendar year, in the event GelTex can obtain Product from a reputable
          source for quantities over [                                   ]*
          kilograms per calendar year and in like quality and under similar
          terms and conditions as set forth in this Agreement at a price which
          is more than [                ]* less than the then existing Contract
          Price,

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential information omitted and filed separately with the Commission

<PAGE>   5
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 5 of 15

          then GelTex shall so notify Salsbury in writing and provide
          documentation of the price it has received from the reputable source;
          provided, however, that GelTex shall be permitted to delete the
          identity of the source in any documents provided. Within fifteen (15)
          days of the date of GelTex's notice, Salsbury shall notify GelTex in
          writing of its decision to match the price offered from the reputable
          source. If GelTex does not receive such notice from Salsbury prior to
          the expiration of the fifteen (15) day response period, then GelTex
          shall be permitted to purchase amounts above [                 ]*
          kilograms from the other reputable source during the remainder of the
          Initial Term or any Renewal Term; however, in no event will GelTex
          purchase less than [               ]* kilograms of Product from
          Salsbury per calendar year at the Contract Price for the remainder of
          the Term of the Agreement.

     3.08 PRICE RENEGOTIATIONS. GelTex shall have the option to reopen price
          discussions once the Product production and sales volume exceeds
          [                        ]* kilograms per calendar year.

ARTICLE IV
DELIVERY AND TITLE
------------------

     4.01 TERMS OF DELIVERY. The Product shall be shipped C.I.F. Charles City,
          Iowa to Dow Specialty Products Company (Midland, MI) and F.O.B.
          Charles City, Iowa to all other Contract Manufacturers unless
          otherwise instructed by GelTex in writing and agreed to by Salsbury.

     4.02 MANUFACTURE OF PRODUCT.

          A.   All Product delivered under this Agreement shall be manufactured
               in compliance with the terms and conditions of the Sublicense
               Agreement.

          B.   The Product shall be manufactured in accordance with all
               applicable regulatory standards including, but not limited to,
               Current Good Manufacturing Practices ("cGMP") and the Technical
               Agreement. Salsbury shall be responsible for maintaining or
               causing to be maintained, on behalf of GelTex, the retention
               samples of the Product required by applicable regulatory
               standards.

          C.   Salsbury shall provide the current Material Safety Data Sheet
               (MSDS) to GelTex for all Product delivered hereunder.

          D.   Salsbury will maintain, and will cause any Affiliate to maintain,
               complete and accurate records relating to the Product and the
               manufacture, packaging and

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential information omitted and filed separately with the Commission

<PAGE>   6
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 6 of 15

               testing thereof for the period required by applicable regulatory
               standards. Without limiting the generality of the foregoing,
               Salsbury shall or shall cause any Affiliate to:

               1)   perform quality assurance and control tests on each lot of
                    Product manufactured before delivery and shall prepare and
                    deliver to GelTex a written report of the results of such
                    tests, with each report setting forth for each lot delivered
                    the items tested, specifications and results in a
                    Certificate of Analysis containing the types of information
                    required by applicable regulatory standards, and

               2)   prepare and maintain for a period of not less than five (5)
                    years and for so long as required under applicable
                    regulatory standards for each lot of Product manufactured a
                    certificate of manufacturing compliance containing the types
                    of information required by applicable regulatory standards,
                    which will certify that the lot of Product was manufactured
                    in accordance with Specifications and cGMPs.

          E.   Each party shall promptly advise the other of any safety or
               toxicity problem of which either party becomes aware regarding
               the Product or intermediates used in the manufacture of the
               Product.

          F.   The parties shall make their best efforts to facilitate the
               incorporation of process improvements approved by GelTex into the
               Product manufacturing scheme. GelTex and Salsbury shall share
               equally in the cost savings resulting from the process
               improvements.

     4.03 INSPECTION. Within a reasonable time of arrival of the Product at
          GelTex's facility or the facility of a Contract Manufacturer, as the
          case may be, the recipient of the Product shall inspect and test the
          Product at its cost. If the party testing the Product finds that the
          Product does not conform to the Specifications, GelTex shall within
          thirty (30) days after the date of such arrival, give Salsbury written
          notice of any claim setting forth the details of such non-conformity
          and any payment for such non-conforming Product shall be delayed until
          conforming Product has been accepted. Salsbury shall replace, at its
          expense, any non-conforming Product within thirty (30) days after
          Salsbury receives the above mentioned written notice. This procedure
          shall continue until such time as the recipient of the Product shall
          determine that the Product conforms to the Specifications. Disputes
          between the parties as to whether all or any part of a shipment
          rejected conforms to the Product Specifications shall be resolved by a
          mutually acceptable third-party testing laboratory.

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   7
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 7 of 15

     4.04 PLANT VISITS. Salsbury shall, and shall cause any Affiliate to permit
          representatives of GelTex and / or its Collaborators, to visit the
          facilities where the Product is manufactured for the purpose of
          reviewing the manufacture and testing of the Product and related batch
          records and of conducting compliance audits associated with cGMPs and
          other regulatory requirements. GelTex agrees to give Salsbury and any
          Affiliate, as the case may be reasonable notice of any proposed visit
          to a Product facility by a GelTex representative or a Collaborator
          representative. Any such visits shall be during normal business hours
          on work days and be subject to a standard confidentiality agreement.
          In addition, Salsbury shall, and shall cause any Affiliate to, permit
          governmental inspectors acting pursuant to statutory authority to
          inspect the facilities where the Product is being manufactured, and to
          review required documentation. Salsbury shall notify GelTex in advance
          of any planned visit by a governmental inspector, and shall notify
          promptly notify GelTex following an unscheduled visit by a
          governmental inspector.

     4.05 AUDIT RIGHTS. Salsbury agrees to provide GelTex with such financial
          information as GelTex may reasonably request in order that GelTex may
          verify that (i) any revisions to the Base Price permitted under
          Section 3.03 hereof have been accurately calculated, and (ii) any cost
          savings discussed in Section 4.02F have been accurately calculated and
          divided.

ARTICLE V
WARRANTIES, [        ]* AND INSURANCE
-------------------------------------

     5.01 WARRANTIES.

          A.   Salsbury warrants that

               1)   Product delivered pursuant to this Agreement (whether
                    manufactured by Salsbury or another Cambrex Affiliate) shall
                    (i) conform with the Specifications, (ii) be manufactured in
                    accordance with cGMPs and all other applicable requirements,
                    (iii) be conveyed with good title, free from any lawful
                    security interests, lien or encumbrance, and (iv) not be
                    adulterated or misbranded within the meaning of the Federal
                    Food, Drug and Cosmetic Act; provided, however, that
                    Salsbury shall not be liable for misbranding or adulteration
                    which is due to any labeling, instructions or packaging
                    provided to Salsbury by GelTex; and,

               2)   the facility used to manufacture the Product is in
                    substantial compliance with all applicable regulatory
                    requirements and there are no pending or

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential Information omitted and filed separately with the Commission

<PAGE>   8
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 8 of 15

                    uncorrected citations or adverse conditions affecting the
                    manufacture of Product noted in any inspection of the
                    facility.

               3)   SALSBURY MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH
                    RESPECT TO THE PRODUCT. ALL OTHER WARRANTIES, EXPRESS OR
                    IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED
                    WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
                    PURPOSE ARE HEREBY DISCLAIMED BY SALSBURY.

          B.   GelTex warrants that it is authorized to license the Patent
               Rights to Salsbury and that the Contract Manufacturers identified
               to Salsbury are authorized and accepted by Nittobo.

          C.   It is understood and agreed that Salsbury has no control over the
               ultimate use of the Product or use of products that include or
               were manufactured with the Product, and Salsbury shall have no
               liability in connection with any such use.

     5.02 SPECIFICATIONS. GelTex shall deliver to Salsbury written notice of any
          required changes to the Specifications, and Salsbury will use its best
          efforts to accommodate such Specification changes. [
                                                                          ]*

     5.03 GELTEX [       ]*. GelTex shall [                               ]*

     5.04 SALSBURY [        ]*. Salsbury will [                             ]*

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential information omitted and filed separately with the Commission

<PAGE>   9
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 9 of 15

     5.05 PATENT [      ]*. [                                             ]*.

     5.06 [              ]* PROCEDURES. A party [                     ]*
          Section 5.03, 5.04, or 5.05 above, shall promptly notify [
                                                                          ]*

     5.07 INSURANCE. Each party warrants to the other that it is currently
          insured and covenants that at all times during the term of this
          Agreement it will maintain a comprehensive general liability insurance
          policy which

          A.   is sufficient to adequately protect against the risks associated
               with its ongoing business, including the risks which might
               possibly arise in connection with the transactions contemplated
               by this Agreement and

          B.   provides that it cannot be terminated or canceled without giving
               the other party thirty (30) days advance written notice.

ARTICLE VI
CONFIDENTIALITY
---------------

     6.01 CONFIDENTIAL INFORMATION. All confidential information furnished in
          writing and designated "CONFIDENTIAL" by GelTex to Salsbury, or any of
          its respective

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---

* Confidential information omitted and filed separately with the Commission

<PAGE>   10
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 10 of 15

          affiliates, or furnished by Salsbury to GelTex or RenaGel LLC or any
          of their affiliates, during the term of this Agreement, relating to
          the subject matter hereof ("Confidential Information") shall be kept
          confidential by the party receiving it, and the party receiving
          Confidential Information shall not make use of it except for purposes
          authorized by this Agreement, nor disclose any Confidential
          Information to any person or firm unless previously authorized in
          writing to do so; provided, however, that the party receiving
          Confidential Information may disclose it as necessary to responsible
          officers, employees and independent contractors for the purpose
          contemplated by this Agreement, provided that such officers, employees
          and independent contractors shall have assumed like obligations of
          confidentiality.

     6.02 OTHER INFORMATION. The foregoing limitations on the use and disclosure
          of Confidential Information shall not apply

          A.   to the disclosure of information as required by any governmental
               regulatory agency by any law or regulation, provided that the
               owner of the Confidential Information has been given prior notice
               of the required disclosure and all parties have taken all
               reasonable steps to limit the required disclosure;

          B.   to information which at the time of disclosure or thereafter
               lawfully becomes a part of the public domain through no fault of
               the receiving party;

          C.   to information which was otherwise in the receiving party's
               lawful possession prior to disclosure as shown by its written
               records; or

          D.   to information which is released from confidential status by
               mutual agreement of the parties.

     6.03 PUBLICITY. Except as may be required by applicable laws and
          regulations or a court of competent jurisdiction, as required to meet
          credit or other financing arrangements, or as required or appropriate
          in the reasonable judgment of either party to satisfy the disclosure
          requirements of any applicable securities law or regulation, neither
          party shall make any public release or other disclosure with respect
          to this Agreement or the terms hereof without the prior consent of the
          other party.

ARTICLE VII
RIGHTS TO PRODUCT
-----------------

     7.01 OWNERSHIP. Any and all improvements, discoveries and/or inventions,
          whether or not patentable, which may be made or conceived by Salsbury
          or any of the other

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   11
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 11 of 15

          Cambrex Affiliates manufacturing Product during the Initial Term or
          any Renewal Term of this Agreement and which is based on the Patent
          Rights, the Product or products using the Product, shall be the sole
          and exclusive property of GelTex. Salsbury shall provide and shall
          cause any such Cambrex Affiliate to provide, full disclosure to GelTex
          of all such improvements, discoveries, and/or inventions described
          above, and shall execute or cause to be executed any and all
          applications, assignments, or other instruments which GelTex shall
          deem necessary or useful in order to apply for and obtain Letters
          Patent of the United States and all foreign countries for discoveries
          and improvements believed to be inventions, and shall assign and
          convey or caused to be assigned and conveyed to GelTex sole and
          exclusive right, title, and interest in and to the discoveries and
          improvements and to all patent applications and patents thereon.
          GelTex will bear the cost of preparation of all such patent
          applications. Notwithstanding the above, GelTex grants Salsbury a
          perpetual, royalty-free, world-wide license for any intellectual
          property (whether or not patentable) made or conceived during the
          Initial Term or any Renewal term related to, or useful in connection
          with the Product manufacturing process for Salsbury's use in the
          manufacture of the Product and any other products.

ARTICLE VIII
TERMINATION FOR CAUSE
---------------------

     8.01 EARLY TERMINATION. This Agreement may be terminated by:

          A.   Salsbury, or

          B.   GelTex as follows:

               1)   By a party immediately upon written notice by another party
                    that it has filed or has had filed against it a petition
                    under the Bankruptcy Act, makes an assignment for the
                    benefits of creditors, has a receiver appointed for it or
                    any of its assets.

               2)   By a party if another party fails to perform or otherwise
                    breaches any of its material obligations hereunder, by
                    giving notice of its intent to terminate and stating the
                    grounds therefor. The party receiving such notice shall have
                    sixty (60) days from receipt thereof if such breach or
                    failure involves a non-monetary obligation and fifteen (15)
                    days if the breach or failure is regarding a monetary
                    obligation, to cure the failure or breach, at which time
                    this agreement shall terminate if such failure or breach has
                    not been cured. In no event, however, shall such notice of
                    termination to terminate be deemed

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   12
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 12 of 15

                    to waive any rights to damages or any other remedy which the
                    party giving notice of breach may have as a consequence of
                    such failure or breach.

     8.02 EFFECT OF TERMINATION. Termination of this Agreement, for whatever
          reason, shall not affect the obligations of specified in Sections
          5.01, 5.03, 5.04, 5.05 or 5.06 or Sections 9.05, 9.07, 9.08, 9.10 or
          9.11, or Articles VI or VII hereunder.

ARTICLE IX
GENERAL PROVISIONS
------------------

     9.01 FORCE MAJEURE. Any delay in the performance of any of the duties or
          obligations of either party hereto (except the payment of money)
          caused by an event outside the affected party's reasonable control
          shall not be considered a breach of this Supply Agreement and the time
          required for performance shall be extended for a period equal to the
          period of such delay. Such events shall include without limitation any
          delay of FDA approval for products incorporating Product; acts of God;
          acts of a public enemy; insurrections; riots; injunctions; embargoes;
          fires; explosions; floods; or other unforeseeable causes beyond the
          reasonable control and without the fault or negligence of the party so
          affected. The party so affected shall give prompt notice to the other
          party of such cause, and shall take whatever reasonable steps are
          appropriate in that party's discretion to relieve the effect of such
          cause as rapidly as possible. Notwithstanding the foregoing or
          anything else in this Agreement to the contrary, should the force
          majeure event result in inability of a party to fully perform
          hereunder for a period of more than three (3) months, the other party
          shall have the right to immediately terminate this Agreement.

     9.02 ASSIGNMENT. No party shall assign this Agreement or any part thereof
          without the prior written consent of the other parties; provided,
          however, a party, without such consent, may assign or sell the same in
          connection with the transfer, license or sale of substantially its
          entire business to which this Agreement pertains, in the event of its
          merger or consolidation with another company or in the event of the
          transfer or sale to a wholly-owned subsidiary.

     9.03 SUCCESSORS IN INTEREST. This Agreement shall be binding upon and inure
          to the benefit of the parties hereto, their subsidiaries, affiliates,
          successors and permitted assigns. Assignment to an Affiliate or
          subsidiary shall not release the party making such assignment from
          responsibility for its obligations under this Agreement.

     9.04 ENTIRE AGREEMENT. This Agreement and the Technical Agreement, together
          shall constitute the entire agreement between the parties hereto and
          shall supersede

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   13
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 13 of 15

          any other agreements, whether oral or written, express or implied, as
          they pertain to the Product. This Agreement may not be changed or
          modified except by written instrument signed by both parties.

     9.05 RELATIONSHIP. The relationship created by this Agreement shall be
          strictly that of the buyer and seller. No party is hereby constituted
          an employee, an agent or legal representative of the other party for
          any purpose whatsoever, and is granted no right or authority hereunder
          to assume or create any obligation, express or implied, or to make any
          representation, warranties or guarantees, except as are expressly
          granted or made in this Agreement.

     9.06 NOTICE. Any notice required hereunder may be served by either party on
          the other by personal delivery, or by sending same, post-prepaid, by
          registered or by certified mail, or sent by facsimile to the
          respective party's address set forth below:

               Salsbury:          Salsbury Chemicals, Inc.
                                  1205 11th Street
                                  Charles City, IA 50616-3466
                                  Attention:  Vice President - Sales & Marketing
                                  (fax 515-228-4152)

               with a copy to:    Cambrex Corporation
                                  One Meadowlands Plaza
                                  East Rutherford, NJ 07073
                                  Attention:  General Counsel
                                  (fax 201-804-9852)

               GelTex:            GelTex Pharmaceuticals, Inc.
                                  153 Second Avenue
                                  Waltham, MA 02154
                                  Attention:  Joseph E. Tyler
                                  (fax 781-895-4982)

               with a copy to:    GelTex Pharmaceuticals, Inc.
                                  153 Second Avenue
                                  Waltham, MA 02154
                                  Attention:  Corporate Counsel
                                  (fax 781-672-5822)

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   14
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 14 of 15

               RenaGel LLC        RenaGel LLC
                                  c/o GelTex Pharmaceuticals, Inc.
                                  153 Second Avenue
                                  Waltham, MA 02154
                                  Attention:  Joseph E. Tyler
                                  (fax 781-895-4981)

          or to such other address as one party may notify the other as provided
          herein.

     9.07 WAIVER. A waiver by any party for a breach of any of the terms of this
          Agreement by any other party shall not be deemed a waiver of any
          subsequent breach of the terms of this Agreement.

     9.08 GOVERNING LAW. This Agreement is to be governed by and construed in
          accordance with the laws of the State of Iowa.

     9.09 SEVERABILITY. If any provision of this Agreement or the application of
          any of such provision to any person or circumstance shall be held
          invalid, illegal or unenforceable in any respect by a court of
          competent jurisdiction, such invalidity, illegality or
          unenforceability shall not affect any other provisions thereof.

     9.10 DISPUTE RESOLUTION. Any controversy or claim arising out of or
          relating to this Agreement, or the breach thereof shall be settled by
          arbitration in accordance with the Rules of the American Arbitration
          Association and judgment upon award rendered by the Arbitrator(s) may
          be entered in any court having jurisdiction thereof. Written notice of
          demand for arbitration shall be filed with the other party to the
          Agreement and with the American Arbitration Association within a
          reasonable time after the dispute has arisen. Any such arbitration
          shall be held in Charles City, Iowa if the arbitration is demanded by
          GelTex, and in Boston, Massachusetts if Salsbury demands the
          arbitration.

     9.11 COUNTERPARTS. This Agreement may be executed in any number of
          counterparts, each of, which once so executed and delivered shall be
          deemed an original, but all of which constitute but one and the same
          Agreement. All headings, captions, exhibits, schedules and tables are
          inserted by convenience of reference only and shall not affect the
          meaning or interpretation of any provision hereof.

                                                                November 9, 1999

                                      INITIAL: GelTex Pharmaceuticals, Inc.:
                                                                             ---
                                                    Salsbury Chemicals Inc.: DPB
                                                                             ---
<PAGE>   15
Poly(allylamine hydrochloride) Supply Agreement
GelTex Pharmaceuticals, Inc. - Salsbury Chemicals Inc.
Page 15 of 15

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written.

WITNESSETH:                     SALSBURY CHEMICALS, INC.

By: /s/ James S. Hanson         By: /s/ Dennis P. Bauer
   -----------------------         --------------------------------------
                                    Dennis P. Bauer, Ph.D.

                                Title: Vice President - Sales & Marketing
                                      -----------------------------------
                                Date:     November 9, 1999              .
                                      -----------------------------------
WITNESSETH:                     GELTEX PHARMACEUTICALS, INC.

By: /s/ Priscilla English       By: /s/ Mark Skaletsky
   -----------------------         --------------------------------------

                                Title: President and CEO
                                      -----------------------------------
                                Date:  December 13, 1999
                                      -----------------------------------<PAGE>   1

                                                                   Exhibit 10.14

                              EMPLOYMENT AGREEMENT

         THIS EMPLOYMENT AGREEMENT (the "Agreement"), made as of this 15th day
of January, 1999, is entered into by Network Plus Corp., a Delaware corporation
with its principal place of business at 234 Copeland Street, Quincy, MA 02169
(the "Company"), and George C. Alex, residing at 18 Lockwood Avenue, Greenwich,
CT 06870 (the "Employee").

         The Company desires to employ the Employee, and the Employee desires to
be employed by the Company. In consideration of the mutual covenants and
promises contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by the parties hereto,
the parties agree as follows:

         1. Term of Employment. The Company hereby agrees to employ the
Employee, and the Employee hereby accepts employment with the Company, upon the
terms set forth in this Agreement, for the period commencing on February 1, 1999
(the "Commencement Date") and ending on the date three (3) years following the
Commencement Date (the "Employment Period"), unless sooner terminated in
accordance with the provisions of Section 4. The Employment Period may be
extended for one or more one-year periods by written agreement of the Company
and the Employee.

         2. Title; Capacity. The Employee shall serve as Executive Vice
President and Chief Financial Officer or in such other position of equal or
greater rank as the Company or its Board of Directors (the "Board") may
determine from time to time. The Employee shall be based at the Company's
headquarters in Quincy, Massachusetts, or such place or places in the
continental United States as the Board and the Employee shall determine. The
Employee shall be subject to
<PAGE>   2
the supervision of, and shall have such authority as is delegated to him by, the
Board, the Chief Executive Officer, or such officer of the Company as may be
designated by the Board. The Employee hereby accepts such employment and agrees
to undertake the duties and responsibilities inherent in such position and such
other duties and responsibilities as the Board or its designee shall from time
to time reasonably assign to him. The Employee agrees to devote his entire
business time, attention and energies to the business and interests of the
Company during the Employment Period. The Employee agrees to abide by the rules,
regulations, instructions, personnel practices and policies of the Company and
any changes therein which may be adopted from time to time by the Company. The
Employee acknowledges receipt of the Company's Employee Handbook as in effect as
of the date of this Agreement.

         3. Compensation and Benefits.

             3.1. Salary. The Company shall pay the Employee, in monthly
installments, an annual base salary of $200,000 for the one-year period
commencing on the Commencement Date. Such salary shall be subject to increase
thereafter as determined by the Board in its sole discretion (after taking into
account the Employee's performance, the Company's performance and any increases
in base salary given to other senior executives of the Company).

             3.2. Fringe Benefits. The Employee shall be entitled to participate
in all bonus and benefit programs that the Company establishes and makes
available to its employees, if any, to the extent that Employee's position,
tenure, salary, age, health and other qualifications make him eligible to
participate. The Employee shall be entitled to three (3) weeks paid vacation per
year, to be taken at such times as may be approved by the Board or its designee.

             3.3. Reimbursement of Expenses. The Company shall reimburse the
Employee for all reasonable travel, entertainment and other expenses incurred or
paid by the Employee in

                                      -2-
<PAGE>   3
connection with, or related to, the performance of his duties, responsibilities
or services under this Agreement, upon presentation by the Employee of
documentation, expense statements, vouchers and/or such other supporting
information as the Company may request, provided, however, that the amount
available for such travel, entertainment and other expenses may be fixed in
advance by the Board or its designee.

             3.4. Moving Expenses. The Company shall reimburse the Employee for
reasonable moving and travel expenses incurred by him in moving himself and his
immediate family from Greenwich, Connecticut to the Boston, Massachusetts
metropolitan area to commence employment with the Company. Such reimbursement
shall be made in accordance with the Company's policy for executive relocations,
a copy of which has been provided to the Employee.

             3.5. Bonus. The Employee shall be entitled to receive an annual
bonus of up to $50,000. The bonus amount shall be determined in the sole
discretion of the Board (or its designee) based upon its determination of the
level of achievement of the goals and objectives that are mutually agreed upon
by the Board (or its designee) and the Employee.

             3.6. Options. The Employee shall be entitled to receive options
under the Company's 1998 Stock Incentive Plan (the "Plan") to purchase the
following number of shares of the Company's Common Stock, $.01 per value per
share, at the following exercise prices: (i) 1,000 shares at $15.00 per share;
(ii) 53,000 shares at $20.00 per share; (iii) 32,000 shares at $30.00 per share;
and (iv) 14,000 shares at $50.00 per share (the "Options"). The Options shall
vest in four equal annual installments on July 15 of each of 1999, 2000, 2001
and 2002, subject to accelerated vesting upon a Change in Control Event (as
defined in the Plan). Each Option

                                      -3-
<PAGE>   4
shall be subject to the terms set forth in, and conditional upon the Employee's
written acceptance of, a written option agreement in the form attached hereto as
Exhibit A.

         4. Employment Termination. The employment of the Employee by the
Company pursuant to this Agreement shall terminate upon the occurrence of any of
the following:

             4.1. Expiration of the Employment Period in accordance with Section
1;

             4.2. At the election of the Company, for cause, immediately upon
written notice by the Company to the Employee. For the purposes of this Section
4.2, cause for termination shall be deemed to exist upon (a) a good faith
finding by the Company of failure of the Employee to perform his assigned duties
for the Company, dishonesty, gross negligence, misconduct, or violation of
Company policy, or (b) the conviction of the Employee of, or the entry of a
pleading of guilty or nolo contendere by the Employee to, any crime involving
moral turpitude or any felony;

             4.3. Thirty days after the death or disability of the Employee. As
used in this Agreement, the term "disability" shall mean the inability of the
Employee, due to a physical or mental disability, for a period of 90 days,
whether or not consecutive, during any 360-day period to perform the services
contemplated under this Agreement. A determination of disability shall be made
by a physician satisfactory to both the Employee and the Company, provided that
if the Employee and the Company do not agree on a physician, the Employee and
the Company shall each select a physician and these two together shall select a
third physician, whose determination as to disability shall be binding on all
parties;

             4.4. At the election of either party, upon not less than three
months' prior written notice of termination.

                                      -4-
<PAGE>   5
         5. Effect of Termination.

             5.1. Termination for Cause or at Election of Employee. In the event
the Employee's employment is terminated for cause pursuant to Section 4.2, or at
the election of the Employee pursuant to Section 4.4, the Company shall pay to
the Employee the compensation and benefits otherwise payable to him under
Section 3 through the last day of his actual employment by the Company.

             5.2. Termination for Death or Disability. If the Employee's
employment is terminated by death, or because of disability pursuant to Section
4.3, (a) the Company shall pay to the estate of the Employee or to the Employee,
as the case may be, (i) the compensation and benefits otherwise payable to him
under Section 3 through the last day of his actual employment by the Company and
(ii) a lump sum payment equal to the lesser of (x) the aggregate amount of base
salary to which the Employee would have been entitled under Section 3(a) above
(based upon the Employee's then-current annual base salary) had he remained
employed by the Company pursuant hereto through the last day of the Employment
Period or (y) six months' base salary, based on the Employee's then-current base
salary, and (b) all of the Options shall vest in full.

             5.3. Termination at Election of Company. If the Employee's
employment is terminated at the election of the Company pursuant to Section 4.4,
(a) the Company shall pay to the Employee (i) the compensation and benefits
otherwise payable to him under Section 3 through the last day of his actual
employment by the Company and (ii) a lump sum payment equal to the Employee's
then-current annual base salary, and (b) all of the Options shall vest in full.

                                      -5-
<PAGE>   6
             5.4. Sale of Shares Following Termination of Employment. In the
event of any termination of the Employee's employment pursuant to Section 4
above, the Employee (or the estate of the Employee) shall not sell more than
15,000 shares of the Company's Common Stock during any period of five (5)
consecutive trading days, provided that the Employee may on up to four (4)
occasions sell a greater number of shares in a block trade.

             5.5. Survival. The provisions of Sections 5.4, 6 and 7 shall
survive the termination of this Agreement.

         6. Non-Compete.

                  (a) In consideration of the obligations of the Company
hereunder, including without limitation the obligations of the Company under
Section 5 above, during the Employment Period and for a period of one (1) year
after the termination or expiration thereof (or three (3) years in the case of
termination at the election of the Company pursuant to Section 4.4 and payment
by the Company of the amount required pursuant to Section 5.3), the Employee
will not directly or indirectly:

                  (i)      as an individual proprietor, partner, stockholder,
                           officer, employee, director, joint venturer,
                           investor, lender, or in any other capacity whatsoever
                           (other than as the holder of not more than one
                           percent (1%) of the total outstanding stock of a
                           publicly held company), engage in the business of
                           developing, producing, marketing or selling products
                           of the kind or type developed or being developed,
                           produced, marketed or sold by the Company while the
                           Employee was employed by the Company; or

                                      -6-
<PAGE>   7
                  (ii)     recruit, solicit or induce, or attempt to induce, any
                           employee or employees of the Company to terminate
                           their employment with, or otherwise cease their
                           relationship with, the Company; or

                  (iii)    solicit, divert or take away, or attempt to divert or
                           to take away, the business or patronage of any of the
                           clients, customers or accounts, or prospective
                           clients, customers or accounts, of the Company which
                           were contacted, solicited or served by the Employee
                           while employed by the Company.

                  (b) If any restriction set forth in this Section 6 is found by
any court of competent jurisdiction to be unenforceable because it extends for
too long a period of time or over too great a range of activities or in too
broad a geographic area, it shall be interpreted to extend only over the maximum
period of time, range of activities or geographic area as to which it may be
enforceable.

                  (c) The restrictions contained in this Section 6 are necessary
for the protection of the business and goodwill of the Company and are
considered by the Employee to be reasonable for such purpose. The Employee
agrees that any breach of this Section 6 will cause the Company substantial and
irrevocable damage and therefore, in the event of any such breach, in addition
to such other remedies which may be available, the Company shall have the right
to seek specific performance and injunctive relief.

         7. Proprietary Information; Other Agreements.

             7.1. Proprietary Information.

                  (a) Employee agrees that all information and know-how, whether
or not in writing, of a private, secret or confidential nature concerning the
Company's business or

                                      -7-
<PAGE>   8
financial affairs (collectively, "Proprietary Information") is and shall be the
exclusive property of the Company. By way of illustration, but not limitation,
Proprietary Information may include products, plans, financial data, personnel
data, computer programs, and customer and supplier lists. Employee will not
disclose any Proprietary Information to others outside the Company or use the
same for any unauthorized purposes without written approval by an officer of the
Company, either during or after his employment, unless and until such
Proprietary Information has become public knowledge without fault by the
Employee.

                  (b) Employee agrees that all files, letters, memoranda,
reports, records, data, or other written or other tangible material containing
Proprietary Information, whether created by the Employee or others, which shall
come into his custody or possession, shall be and are the exclusive property of
the Company to be used by the Employee only in the performance of his duties for
the Company.

                  (c) Employee agrees that his obligation not to disclose or use
information, know-how and records of the types set forth in paragraphs (a) and
(b) above, also extends to such types of information, know-how, records and
tangible property of customers of the Company or suppliers to the Company or
other third parties who may have disclosed or entrusted the same to the Company
or to the Employee in the course of the Company's business.

             7.2. Other Agreements. Employee hereby represents that he is not
bound by the terms of any agreement with any previous employer or other party to
refrain from using or disclosing any trade secret or confidential or proprietary
information in the course of his employment with the Company or to refrain from
competing, directly or indirectly, with the business of such previous employer
or any other party. Employee further represents that his performance of all the
terms of this Agreement and as an employee of the Company does not and

                                      -8-
<PAGE>   9
will not breach any agreement to keep in confidence proprietary information,
knowledge or data acquired by him in confidence or in trust prior to his
employment with the Company.

         8. Notices. All notices required or permitted under this Agreement
shall be in writing and shall be deemed effective upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail,
postage prepaid, addressed to the other party at the address shown above, or at
such other address or addresses as either party shall designate to the other in
accordance with this Section 8.

         9. Pronouns. Whenever the context may require, any pronouns used in
this Agreement shall include the corresponding masculine, feminine or neuter
forms, and the singular forms of nouns and pronouns shall include the plural,
and vice versa.

         10. Entire Agreement. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement.

         11. Amendment. This Agreement may be amended or modified only by a
written instrument executed by both the Company and the Employee.

         12. Governing Law. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the Commonwealth of Massachusetts.

         13. Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of both parties and their respective successors and
assigns, including any corporation with which or into which the Company may be
merged or which may succeed to its assets or business, provided, however, that
the obligations of the Employee are personal and shall not be assigned by him.

                                      -9-
<PAGE>   10
         14. Miscellaneous.

             14.1. No delay or omission by the Company in exercising any right
under this Agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective
only in that instance and shall not be construed as a bar or waiver of any right
on any other occasion.

             14.2. The captions of the sections of this Agreement are for
convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement.

             14.3. In case any provision of this Agreement shall be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of
the remaining provisions shall in no way be affected or impaired thereby.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year set forth above.

                                   NETWORK PLUS CORP.

                                   By:  /s/ Robert T. Hale, Jr.
                                       --------------------------------------
                                   Title:  President and Chief Executive Officer

                                   EMPLOYEE

                                       /s/ George Alex
                                       --------------------------------------
                                   George C. Alex

                                      -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]